Back to Search
JOHN BUSE, MD
MD
Endocrinology, Diabetes & Metabolism Physician
NPI: 1336164680IndividualAccepts Medicare
Specialties, Licenses & Credentials
Endocrinology, Diabetes & Metabolism PhysicianPrimary
Internal Medicine — Endocrinology, Diabetes & Metabolism
Code: 207RE0101X
9400739(NC)
Education
DUKE UNIVERSITY SCHOOL OF MEDICINE
Class of 1986
Research & Publications (20)
DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes.
PMID 19336625·Diabetes Care·2009
4-observational
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
PMID 19515413·Lancet·2009
4-observational
Are prescribing patterns of antidiabetic medications influenced by fears of litigation?
PMID 18560400·Nat Clin Pract Endocrinol Metab·2008
8-other
A dead heat: target normal glucose levels in the intensive care unit--but with caution.
PMID 18392805·Diabetologia·2008
8-other
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.
PMID 17192355·Diabetes Care·2007
6-review
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
PMID 17379054·Clin Ther·2007
4-observational
Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon.
PMID 15752929·Endocrinol Metab Clin North Am·2005
6-review
Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
PMID 16199244·Clin Ther·2005
4-observational
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
PMID 15504997·Diabetes Care·2004
3-trial
The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.
PMID 14746579·Diabetes Obes Metab·2004
6-review
Should postprandial glucose be routinely measured and treated to a particular target? No!
PMID 12716828·Diabetes Care·2003
6-review
Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker.
PMID 12828817·Diabetes Technol Ther·2003
4-observational
A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States.
PMID 12654411·J Clin Epidemiol·2003
8-other
Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes.
PMID 11913675·J Clin Psychiatry·2002
6-review
Thiazolidinediones in the treatment of type 2 diabetes: a clinician's perspective.
PMID 11183423·Am J Manag Care·2000
8-other
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP).
PMID 19626663·Diabetes Metab Res Rev·2009
4-observational
Clinical experience with continuous glucose monitoring in adults.
PMID 19469683·Diabetes Technol Ther·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 101 MANNING DR
CHAPEL HILL, NC 27599 - Phone
- (919) 966-4996
Quick Facts
- NPI
- 1336164680
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 40
- Publications
- 20
Are you this provider?
Claim Your Profile